We are live on ! Find out more
PAP

Persistent Asset Partners Portfolio holdings

AUM $268M
1-Year Est. Return 158.98%
This Fund
S&P 500
This Quarter Est. Return
+35.4%
1 Year Est. Return
+158.98%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$268M
AUM Growth
+$45.6M
Cap. Flow
+$18.2M
Cap. Flow %
6.78%
Top 10 Hldgs %
33.7%
Holding
508
New
146
Increased
78
Reduced
73
Closed
186

Top Buys

1
TSEM icon
Tower Semiconductor
TSEM
+$9.09M
2
LITE icon
Lumentum
LITE
+$8.24M
3
GLW icon
Corning
GLW
+$6.49M
4
INTC icon
Intel
INTC
+$5.94M
5
ALAB icon
Astera Labs
ALAB
+$4.77M

Top Sells

1
CNC icon
Centene
CNC
+$9.07M
2
MOH icon
Molina Healthcare
MOH
+$8.9M
3
ELV icon
Elevance Health
ELV
+$8.08M
4
BTSG icon
BrightSpring Health Services
BTSG
+$3.52M
5
TERN
Terns Pharmaceuticals
TERN
+$2.78M

Sector Composition

1 Technology 44.62%
2 Healthcare 29.67%
3 Financials 9.04%
4 Consumer Discretionary 3.92%
5 Energy 3.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRE icon
176
Spyre Therapeutics
SYRE
$8.17B
$242K 0.09%
4,803
+2,557
+114% +$96.4K
DBVT
177
DBV Technologies
DBVT
$880M
$238K 0.09%
11,392
+5,373
+89% +$112K
REPL icon
178
PUT
Replimune Group
REPL
$799M
$237K 0.09%
+1,240
New +$9.48K
ANL
179
Adlai Nortye
ANL
$731M
$233K 0.09%
+33,732
New +$225K
ZLAB icon
180
Zai Lab
ZLAB
$2.34B
$232K 0.09%
12,339
– –
CRWV
181
CoreWeave
CRWV
$39.8B
$224K 0.08%
+2,892
New +$251K
EDU icon
182
New Oriental
EDU
$7.87B
$224K 0.08%
3,956
-7,869
-67% -$450K
PHVS icon
183
Pharvaris
PHVS
$2.35B
$223K 0.08%
+7,904
New +$211K
SDRL icon
184
Seadrill
SDRL
$2.64B
$223K 0.08%
+4,961
New +$203K
FHTX icon
185
Foghorn Therapeutics
FHTX
$298M
$223K 0.08%
46,644
-464
-1% -$2.55K
AMRX icon
186
Amneal Pharmaceuticals
AMRX
$5.76B
$221K 0.08%
+17,808
New +$239K
EQ icon
187
Equillium
EQ
$158M
$220K 0.08%
110,117
+16,994
+18% +$28K
KTTA icon
188
Pasithea Therapeutics
KTTA
$15.3M
$216K 0.08%
290,555
– –
ENTA icon
189
Enanta Pharmaceuticals
ENTA
$384M
$209K 0.08%
16,525
-941
-5% -$12.6K
SRZN icon
190
Surrozen
SRZN
$241M
$208K 0.08%
7,143
+2,784
+64% +$66.7K
XERS icon
191
Xeris Biopharma Holdings
XERS
$1.5B
$207K 0.08%
35,661
-9,948
-22% -$66K
SLDB icon
192
Solid Biosciences
SLDB
$891M
$202K 0.08%
+27,990
New +$180K
LNTH icon
193
Lantheus
LNTH
$6.84B
$200K 0.07%
+2,642
New +$190K
CYTK icon
194
CALL
Cytokinetics
CYTK
$10.9B
$197K 0.07%
+231
New +$14.7K
BNTC icon
195
Benitec Biopharma
BNTC
$435M
$195K 0.07%
18,307
-2,446
-12% -$28.3K
REPL icon
196
Replimune Group
REPL
$799M
$195K 0.07%
25,445
-36,043
-59% -$276K
LRMR icon
197
Larimar Therapeutics
LRMR
$381M
$190K 0.07%
+42,124
New +$168K
CAPR icon
198
PUT
Capricor Therapeutics
CAPR
$1.11B
$188K 0.07%
1,578
+1,045
+196% +$27.8K
AVBP icon
199
ArriVent BioPharma
AVBP
$1.53B
$187K 0.07%
8,108
+145
+2% +$3.27K
ANNX icon
200
Annexon
ANNX
$965M
$186K 0.07%
33,625
-60,032
-64% -$338K
6 7
8
9 10

Similar funds

VC
VarCov Co Darien, Connecticut $268M AUM
AL
AIP LLC New York $268M AUM 40.4% 1-Year Est. Return
FC
Foursixthree Capital New York $268M AUM 115.24% 1-Year Est. Return
NF
Nvest Financial Portsmouth, New Hampshire $268M AUM 22.87% 1-Year Est. Return
PF
Prosperitas Financial Valencia, California $268M AUM 32.64% 1-Year Est. Return
UI
Untitled Investments New York $269M AUM 11.35% 1-Year Est. Return
SSWM
Strait & Sound Wealth Management San Francisco, California $269M AUM 22.03% 1-Year Est. Return
AC
Applied Capital Little Rock, Arkansas $268M AUM 16.92% 1-Year Est. Return

Persistent Asset Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Persistent Asset Partners held 508 positions worth $268M, up 20% from $223M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Persistent Asset Partners deployed $18.2M of net new capital in Q1 2026, opening 146 new positions and adding to 78 existing holdings. Its largest new stake was Tower Semiconductor: 67,608 shares worth $11.9M.

By sector, the portfolio is most concentrated in Technology at 45% of assets, up from 14% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was Terns Pharmaceuticals, an estimated $2.78M trimmed.

  • Persistent Asset Partners's largest Q1 2026 buy was Tower Semiconductor: 67,608 shares worth $11.9M.
  • Persistent Asset Partners added most to Lumentum in Q1 2026, an estimated $8.24M increase.
  • Persistent Asset Partners's biggest Q1 2026 reduction was Terns Pharmaceuticals, cutting an estimated $2.78M.
  • Persistent Asset Partners fully exited Centene in Q1 2026, selling an estimated $9.07M.
  • Persistent Asset Partners's ten largest holdings make up 34% of its $268M portfolio in Q1 2026.
  • Persistent Asset Partners opened 146 new positions and closed 186 in Q1 2026.
  • Persistent Asset Partners's portfolio value rose 20% quarter-over-quarter to $268M.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.